MedTrace Logo

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

NCT02880410 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2024-04-12

No results posted yet for this study

Summary

Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System in combination with standard of care radiation therapy and temozolomide for the treatment of newly diagnosed glioblastomas (GBM).

Conditions

Interventions

DEVICE

NeuroBlate System

Laser Interstitial Thermal Therapy

DRUG

Radiation therapy and temozolomide

Radiation therapy and temozolomide

Sponsors & Collaborators

  • Monteris Medical

    lead INDUSTRY

Principal Investigators

  • Manmeet Ahluwalia, MD · The Cleveland Clinic

  • Sujit Prabhu, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-15
Primary Completion
2018-09-14
Completion
2018-09-14
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880410 on ClinicalTrials.gov